The New Drug Pipeline Monitor: A New Phase for NPDUIS

1
The New Drug Pipeline Monitor A New Phase for
NPDUIS

• This presentation will probably involve audience
  discussion, which will create action items. Use
  PowerPoint to keep track of these action items
  during your presentation
• In Slide Show, click on the right mouse button
• Select Meeting Minder
• Select the Action Items tab
• Type in action items as they come up
• Click OK to dismiss this box
• This will automatically create an Action Item
  slide at the end of your presentation with your
  points entered.

• Presentation by
• Rebecca Szilagyi, MPH
• Economist, Policy and Economic Analysis
• to
• 2008 CADTH Invitational Symposium
• April 27-29, 2008

2
Overview

• History of NPDUIS
• New Drug Pipeline Monitor (NDPM)- History and
  First Edition
• NDPM Second Phase
• Potential Impact Field
• Drug Class Profile
• Looking Forward

3
National Prescription Drug Utilization
Information System

• NPDUIS established in September 2001 by F/P/T
  Ministers of Health
• Responsibilities of PMPRB established by the
  Minister of Health, pursuant to Section 90 of the
  Patent Act
• Purpose to facilitate informed administration
  of public drug plans in Canada by providing
• Timely, standardized and comparative prescription
  drug information from participating public drug
  plans in response the priorities identified by
  the F/P/T Steering Committee
• Critical analyses of price, utilization and cost
  trends
• Collaborative initiative between CIHI and the
  PMPRB

4
New Drug Pipeline Monitor (NDPM)

• Developed in response to repeated requests from
  F/P/T drug plan managers
• Strongly endorsed by the NPDUIS Steering
  Committee as a useful planning tool
• A product of NPDUIS, the NDPM is an information
  only tool and does not reflect the views of the
  PMPRB or impact the PMPRB role in ensuring that
  the prices of patented medicines sold in Canada
  are not excessive

5
New Drug Pipeline Monitor (NDPM)

• Identifies new drugs and provides updates on
  those previously selected
• Web-based tool that summarizes information on new
  drugs in the pipeline that are
• Stage III drugs expected to be launched in Canada
  within 2-5 years, and
• Expected to have a significant impact in terms of
  therapeutic value

6
Findings from First Edition

• Over 21,000 drugs in the BioPharm Insight
  database
• Of the 1516 in Phase III (or with NDA/BLA filed)
  over one third were Cancer drugs
• 10 drugs chosen for NDPM

7
NDPM Second Phase

• Purpose is two-fold
• Update the list of drugs identified in the first
  edition and explain methodology used to do so
• Includes addition of new drugs and removal of
  drugs that are no longer included in the pipeline
• Profile a class of drugs identified in the
  previous edition including
• Condition treated
• Market analysis with key potential cost drivers
• Not intended to be an in depth budget impact
  analysis

8
New Drugs Identified

• Plerixafor (Mozobil)
• ATC L03 - Immunostimulants
• Multiple Myeloma, Non-Hodgkins
• Lymphoma
• Tolvaptan
• ATC C03 - Diuretics
• Congestive Heart Failure,
• Hyponatremia
• Rivaroxaban (Xarelto, Factor Xa Inhibitor)
• ATC B01 - Antithrombotic agents
• Prevention of Venous thromboembolism (VTE),
• Acute Coronary Syndrome Stroke
• Eculizumab (Soliris)
• ATC L04 - Immunosuppressive agents
• Paroxysmal Nocturnal Hemoglobinuria
• (PNH)

• Sapropterin (Kuvan, Phenoptin)
• ATC A16 - Other alimentary
• tract and metabolism products
• Phenylketonuria (PKU)
• Ecallantide (Dx-88)
• ATC B02 - Antihemorrhagics
• Hereditary angioedema (HAE)
• Cinryze(C1-esterase inhibitor (C1-INH))
• ATC B02 Antihemorrhagics
• Hereditary angioedema (HAE)

9
Potential Impact Field

• Second and subsequent phases will include
  Potential Impact field
• Used to gauge the potential impact the drug may
  have on treatment outcomes as low, medium or high
• Information gathered from financial and
  pharmaceutical sectors, therapeutic efficacy,
  press releases and other available information
  (i.e. international pricing where available)
• All drugs included are assumed to have a
  significant impact (as per NDPM criteria)

10
Drug Class Profile

• Cancer drugs
• Half the drugs identified in the first phase were
  Cancer drugs
• Direct impact on quality of life, length of time
  to progression
• Information about treatment history, classes of
  treatment and trends in Cancer spending in last 5
  years

11
Sources of Information

• NDPM utilizes information from a variety of
  sources including (but not limited to)
• BioPharm Insight database
• Company publications and projections
• IMS data
• Academic and government publications
• Information from other jurisdictions if available

12
Interactive Website in development

• Decision to develop website based on several
  factors
• Recognition that drugs will be added to the NDPM
  faster then they are removed
• The need to update the status of drugs more
  frequently than the web based publications
• Interest from users for an interactive format
• Ability to query and narrow in on a specific drug
  of interest

13
Benefits of New Format

• Allows NPDUIS to update information as frequently
  as required
• Ability of user to pinpoint exact area of
  interest through table of contents tool
• Users will be able to search for a specific drug,
  see history and updates and export their
  selections
• Hyperlinks will allow users to access archived
  versions of published reports
• All information is available in French and English

14
Looking forward

• Begin work on the third annual publication and
  summary
• Identify new sources of information for Market
  Analysis and Potential Impact fields as they
  become available
• Update and evergreen the list

15

• Thank you